Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Molecular Diagnostics in Cytopathology
Molecular diagnostics are increasingly used to help guide targeted therapy in solid organ tumors and hematologic malignancies. A large proportion of molecular testing is performed on limited-volume samples obtained via minimally invasive techniques, such as fine needle aspiration. Increasingly, cytopathologists play an essential role in this process, both in the triage of specimens during rapid on-site evaluation and in the evaluation of archival samples to determine suitability for ancillary testing. Therefore, it is imperative that practicing cytopathologists stay abreast of up-to-date diagnostic, prognostic, and predictive ancillary tests that can be used on limited cytologic material. Th...
Fast Facts: EGFR Exon 20 Insertion Mutations in NSCLC
Lung cancer is still a major cause of death globally, but the development of personalized, precision medicine has had a marked effect on treatment management and improved clinical outcomes, particularly for those with advanced stage non-small-cell lung cancer (NSCLC). EGFR mutations are the third most common mutation found in patients with advanced stage NSCLC. First-line treatment with a traditional epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is indicated for most patients, but not for patients with EGFR exon 20 insertion mutations (ex20ins). Instead, recent approvals of an EGFR ex20ins-specific TKI (mobocertinib) and a bispecific antibody (amivantamab) targeting both EGFR and mesenchymalepithelial transition factor (MET) offer the potential for improved outcomes in this patient population. Furthermore, new approaches to treatment continue to be developed and trials for new agents with greater activity against ex20ins mutations are ongoing. Table of Contents: • EGFR and mutations • EGFR mutation testing • Treatment decisions • Therapies in development
Fast Facts: Comprehensive Genomic Profiling
Cancer is a multifaceted disease in which genetic changes induce uncontrolled tumor growth. Genomic characterization of cancer is now leading to better diagnostic, prognostic and predictive biomarkers, and effective individualized management. 'Fast Facts: Comprehensive Genomic Profiling' provides a crash course in the science, methods and application of genomic profiling. Assuming only the most basic knowledge – or memory – of cell biology, the authors provide an overview of DNA and RNA biology and next-generation sequencing. This sets in context the descriptions of prognostic and predictive biomarkers for different cancer types and genomic-based treatments. Finally, but importantly, some of the practicalities of gaining and interpreting genomic information are described. Whether you need a primer or a refresher, this short colorful book demystifies this complex subject. Contents: • Genetic mutations and biomarkers • Understanding next-generation sequencing • Elements of comprehensive genomic profiles • Role in precision oncology • Predictive and prognostic biomarkers • Overcoming barriers to genotype-directed therapy
Liquid Biopsy in Cancer Patients
This text is designed to provide readers with a useful and comprehensive resource and state-of-the-art overview about the new, growing and fast-expanding field of “liquid biopsy” for the management of cancer patients. The liquid biopsy represents an important turning point in oncology since it provides a tool for a serial monitoring of disease. Liquid biopsy is our “hand lens” to follow molecular changes that characterize tumor development and progression. The book provide a unique and valuable resource on the clinical relevance of liquid biopsy as well as on the technical aspects of liquid biopsy analysis. All invited authors are recognized experts in their field. Liquid Biopsy in Cancer Patients: The Hand Lens for Tumor Evolution is targeted to resident and fellows physicians, medical oncologists, molecular biologists and biotechnologists.
Practical Medical Oncology Textbook
This textbook combines essential information on clinical cancer medicine with a guide to the latest advances in molecular oncology and tumor biology. Providing a systematic overview of all types of solid tumors, including epidemiology and cancer prevention, genetic aspects of hereditary cancers, differential diagnosis, typical signs and symptoms, diagnostic strategies and staging, and treatment modalities, it also discusses new and innovative cancer treatments, particularly targeted therapy and immunotherapy. Expert commentaries at the end of each chapter highlight key points, offer insights, suggest further reading and discuss clinical application using case descriptions. This textbook is an invaluable, practice-oriented tool for medical students just beginning their clinical oncology studies, as well as for medical oncology residents and young professionals.
Diagnostic, Prognostic and Therapeutic Value of Gene Signatures
Gene expression studies have revealed diagnostic profiles and upregulation of specific pathways in many solid tumors. The explosion of new information in gene expression profiling could potentially lead to the development of tailored treatments in many solid tumors. In addition many studies are ongoing to validate these signatures also in predicting response to hormonal, chemotherapeutic and targeted agents in breast cancer as well as in other tumors. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures provides readers a useful and comprehensive resource about the range of applications of microarray technology in oncological diseases. Topics covered include gene signatures and soft tissue sarcomas, prognostic relevance of breast cancer signatures, gene expression profiling of colorectal cancer and liver metastasis, gene signatures in GISTs, CNVs and gene expression profiles in pancreatic cancer, and gene signatures in head/neck, lung and gastric tumors. Diagnostic, Prognostic and Therapeutic Value of Gene Signatures will be of great value to residents and fellows, physicians, pathologists and medical oncologists.
The International System for Serous Fluid Cytopathology
This book is the culmination of an international effort to bring consistency and diagnostic efficiency to effusion cytology for the sake of patient care. The authors recognize special challenges in serous fluid cytopathology, such as reporting the presence of Mullerian epithelium in peritoneal fluids. What is an appropriate serous fluid volume to ensure adequacy? How should mesothelial proliferations be reported and is it appropriate to make an interpretation of malignant mesothelioma? How specific should a report be regarding the origin and subtyping of tumors found in serous fluids? What are the appropriate quality monitors for this specimen type? Special chapters on considerations for per...
Molecular Pathology
Practical overview of current molecular techniques and their applications in each organ system, for practising and trainee pathologists.
Thyroid FNA Cytology
Zusammenfassung: This is the third edition of a well-received book that recapitulates the thyroid fine-needle aspiration (FNA) cytology. It covers the basics and critical principles of thyroid cytopathology, addresses technical aspects, and presents the latest breakthrough events in the field, including the new editions of the WHO classification of thyroid tumors and the Bethesda system for reporting thyroid cytopathology. Thyroid FNA Cytology, The Third Edition is a practical handbook for cytopathologists, pathologists, cytotechnologists, endocrinologists, thyroid surgeons, radiologists, thyroid cancer patients, and their families. This edition covers more topics than the previous editions and invites authors from 20 countries from Asia, Europe, and America. It should serve as an individualized guide to readers practicing in various geographic areas with different medical settings and social resources. The book provides multiple chapters on differential diagnosis and pitfalls to show the unique approaches in many countries. The book will broaden their perspectives and serve as a foundation for further advancement in this field
Next Generation Sequencing Based Diagnostic Approaches in Clinical Oncology
Dr. Anton Buzdin (AB) is employed by Omicsway Corp. (USA). AB received grants from Amazon and Microsoft Azure to support cloud computations. Dr. Xinmin Li is director of JCCC Shared Genomics Resource, the University of California, Los Angeles, CA Dr. Ye Wang is Director of Gene testing Department (Core Lab) of Qingdao Central Hospital, the Second Affiliated Hospital of Qingdao University
